The search for a COVID-19 cure has sparked enormous public excitement, and monoclonal antibody cocktails—especially REGN-COV2—have quickly risen to the spotlight following high-profile endorsements. Early trial results suggest these lab-engineered antibodies can lower viral load and reduce medical visits in outpatients, but the evidence is still based on relatively small studies with limited diversity and short follow-up. Important uncertainties remain, including who benefits most, how feasible mass manufacturing would be, and whether real-world delivery challenges could limit impact. Antibody therapies also appear to work best early in infection, requiring rapid testing and timely access—conditions not easily met during surges. While encouraging, the current data are far from definitive, and large, pragmatic RCTs are still needed before monoclonal antibodies can be considered a reliable solution.